Skip to main content
. 2020 Oct 23;9(11):1040. doi: 10.3390/antiox9111040

Figure 1.

Figure 1

Auranofin attenuates body weight gain and the epididymal fat pad in the high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) mouse model. Animals were fed a 60% HFD (60% of calories from fat) and/or a regular diet and also received intraperitoneal injection of auranofin (10 mg/kg) and/or normal saline for 8 weeks. (A) Representative photographic images of the whole mouse body, liver, and epididymal fat pad specimens in each group. (B) Body weight gain for 8 weeks. Data are expressed as the mean ± SD (n = 10). * p < 0.05, ** p < 0.01, and *** p < 0.001 compared with the normal group. ## p < 0.01 and ### p < 0.001 compared with HFD group. (C–F) The average values for body weight, rate of weight gain, liver and epididymal fat pad after the study period. Data are expressed as the mean ± SD (n = 8). *** p < 0.001 compared with the normal group. ### p < 0.001 compared with HFD group. N, normal group; HFD, HFD fed group; HFD+AF, HFD fed and auranofin injection group; AF, auranofin injection group.